阿立哌唑片联合文拉法辛缓释片治疗伴抑郁症状精神分裂症的疗效观察

The clinical observation of aripiprazole combined with Venlafaxine Sustained-Release Tablets in the treatment of schizophrenia with depressive symptoms

目的探讨采用阿立哌唑片联合文拉法辛缓释片治疗伴有抑郁症状的精神分裂症患者的临床疗效。方法选取患有精神分裂症且经汉密尔顿抑郁量表(HAMD)评估后确诊为伴抑郁症状的70例患者,随机均分为对照组与治疗组,对照组患者采用阿立哌唑片进行治疗,治疗组患者采用阿立哌唑片与文拉法辛缓释片进行联合治疗,8周为1个疗程,对两组患者1个疗程后的临床疗效、HAMD评分、不良反应量表(TESS)评分以及不良反应情况进行对照比较。结果开始治疗后第2、4、8周时对两组患者进行HAMD评分,结果显示治疗组患者评分明显低于对照组,差异具有显著性(P<0.05);治疗组临床疗效明显优于对照组,差异具有显著性(P<0.05);治疗组患者TESS评分明显低于对照组,差异具有显著性(P<0.05)。结论采用阿立哌唑片联合文拉法辛缓释片治疗精神分裂症伴抑郁症状,临床疗效显著,患者耐受性好,见效较快,具有临床应用及推广价值。

Objective To study the clinical effect of treating schizophrenia with depressive symptoms using aripiprazole combined with Venlafaxine Sustained-Release Tablets. Method Chose 70 patients evaluated by HAMD to divide into study group and control group. Patients in control group were treated with aripiprazole, and the study group were treated with aripiprazole combined with Venlafaxine Sustained-Release Tablets. The course of treatment was 8 weeks, compared the effect of two groups. Result The score of HAMD on the 2, 4, 8 week in study group was significantly lower than control group（P〈0.05）. The clinical effect of study group was significantly better than control group（P〈0.05）. The score of TESS in study group was lower than control group（P〈0.05）. Conclusion Treating schizophrenia with depressive symptoms using aripiprazole combined with Venlafaxine Sustained-Release Tablets is effective to improve the treatment effect and worth to extend in clinic.